{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T19:03:28Z","timestamp":1792263808649,"version":"4.4.0"},"reference-count":70,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T00:00:00Z","timestamp":1644969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T00:00:00Z","timestamp":1644969600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Cell Commun. Signal."],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s12079-022-00672-4","type":"journal-article","created":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T20:02:31Z","timestamp":1645041751000},"page":"601-608","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["The network map of urotensin-II mediated signaling pathway in physiological and pathological conditions"],"prefix":"10.1002","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9556-3150","authenticated-orcid":false,"given":"D. A. B.","family":"Rex","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4930-2590","authenticated-orcid":false,"given":"G. P.","family":"Suchitha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0322-2448","authenticated-orcid":false,"given":"Akhina","family":"Palollathil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0610-4663","authenticated-orcid":false,"given":"Anagha","family":"Kanichery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6206-2384","authenticated-orcid":false,"given":"T. S. Keshava","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0899-2839","authenticated-orcid":false,"given":"Shobha","family":"Dagamajalu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,2,16]]},"reference":[{"issue":"6750","key":"672_CR1","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/45809","volume":"401","author":"RS Ames","year":"1999","unstructured":"Ames RS, Sarau HM, Chambers JK, Willette RN, Aiyar NV, Romanic AM, Louden CS, Foley JJ, Sauermelch CF, Coatney RW, Ao Z, Disa J, Holmes SD, Stadel JM, Martin JD, Liu WS, Glover GI, Wilson S, McNulty DE, Ellis CE, Elshourbagy NA, Shabon U, Trill JJ, Hay DW, Ohlstein EH, Bergsma DJ, Douglas SA (1999) Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 401(6750):282\u2013286","journal-title":"Nature"},{"issue":"2","key":"672_CR2","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.yjmcc.2006.05.008","volume":"41","author":"N Bousette","year":"2006","unstructured":"Bousette N, Hu F, Ohlstein EH, Dhanak D, Douglas SA, Giaid A (2006) Urotensin-II blockade with SB-611812 attenuates cardiac dysfunction in a rat model of coronary artery ligation. J Mol Cell Cardiol 41(2):285\u2013295","journal-title":"J Mol Cell Cardiol"},{"issue":"12","key":"672_CR3","doi-asserted-by":"publisher","first-page":"5148","DOI":"10.1096\/fj.14-249771","volume":"28","author":"C Brule","year":"2014","unstructured":"Brule C, Perzo N, Joubert JE, Sainsily X, Leduc R, Castel H, Prezeau L (2014) Biased signaling regulates the pleiotropic effects of the urotensin II receptor to modulate its cellular behaviors. FASEB J 28(12):5148\u20135162","journal-title":"FASEB J"},{"issue":"01\/01","key":"672_CR4","first-page":"158","volume":"1975","author":"LE Carlson","year":"1975","unstructured":"Carlson LE, Childress DS (1975) The lift lock: a device to increase the lifting ability of dual-control prostheses. Bull Prosthet Res 1975(01\/01):158\u2013168","journal-title":"Bull Prosthet Res"},{"key":"672_CR5","doi-asserted-by":"publisher","first-page":"76","DOI":"10.3389\/fendo.2017.00076","volume":"8","author":"H Castel","year":"2017","unstructured":"Castel H, Desrues L, Joubert JE, Tonon MC, Prezeau L, Chabbert M, Morin F, Gandolfo P (2017) The G protein-coupled receptor UT of the neuropeptide urotensin II displays structural and functional chemokine features. Front Endocrinol (Lausanne) 8:76","journal-title":"Front Endocrinol (Lausanne)"},{"key":"672_CR6","doi-asserted-by":"publisher","first-page":"724670","DOI":"10.1155\/2014\/724670","volume":"2014","author":"HH Chao","year":"2014","unstructured":"Chao HH, Sung LC, Chen CH, Liu JC, Chen JJ, Cheng TH (2014) Lycopene inhibits urotensin-II-induced cardiomyocyte hypertrophy in neonatal rat cardiomyocytes. Evid Based Complement Alternat Med 2014:724670","journal-title":"Evid Based Complement Alternat Med"},{"issue":"9","key":"672_CR7","doi-asserted-by":"publisher","first-page":"e106812","DOI":"10.1371\/journal.pone.0106812","volume":"9","author":"YL Chen","year":"2014","unstructured":"Chen YL, Tsai YT, Lee CY, Lee CH, Chen CY, Liu CM, Chen JJ, Loh SH, Tsai CS (2014) Urotensin II inhibits doxorubicin-induced human umbilical vein endothelial cell death by modulating ATF expression and via the ERK and Akt pathway. PLoS ONE 9(9):e106812","journal-title":"PLoS ONE"},{"issue":"5","key":"672_CR8","doi-asserted-by":"publisher","first-page":"6904","DOI":"10.3892\/mmr.2017.7424","volume":"16","author":"S Chen","year":"2017","unstructured":"Chen S, Wang Y, Wan Y (2017) Urotensin II enhances transforming growth factorbeta1 expression and secretion in the kidney during aristolochic acid nephropathy. Mol Med Rep 16(5):6904\u20136909","journal-title":"Mol Med Rep"},{"issue":"5","key":"672_CR9","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1111\/j.1538-7836.2008.02923.x","volume":"6","author":"P Cirillo","year":"2008","unstructured":"Cirillo P, De Rosa S, Pacileo M, Gargiulo A, Angri V, Fiorentino I, Prevete N, Petrillo G, De Palma R, Leonardi A, De Paulis A, Chiariello M (2008) Human urotensin II induces tissue factor and cellular adhesion molecules expression in human coronary endothelial cells: an emerging role for urotensin II in cardiovascular disease. J Thromb Haemost 6(5):726\u2013736","journal-title":"J Thromb Haemost"},{"issue":"1","key":"672_CR10","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1124\/jpet.104.068320","volume":"311","author":"M Clozel","year":"2004","unstructured":"Clozel M, Binkert C, Birker-Robaczewska M, Boukhadra C, Ding SS, Fischli W, Hess P, Mathys B, Morrison K, Muller C, Muller C, Nayler O, Qiu C, Rey M, Scherz MW, Velker J, Weller T, Xi JF, Ziltener P (2004) Pharmacology of the urotensin-II receptor antagonist palosuran (ACT-058362; 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea sulfate salt): first demonstration of a pathophysiological role of the urotensin system. J Pharmacol Exp Ther 311(1):204\u2013212","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"672_CR11","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s12079-020-00581-4","volume":"15","author":"S Dagamajalu","year":"2021","unstructured":"Dagamajalu S, Rex DAB, Gopalakrishnan L, Karthikkeyan G, Gurtoo S, Modi PK, Mohanty V, Mujeeburahiman M, Soman S, Raju R, Tiwari V, Prasad TSK (2021) A network map of endothelin mediated signaling pathway. J Cell Commun Signal 15(2):277\u2013282","journal-title":"J Cell Commun Signal"},{"issue":"1","key":"672_CR12","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s12079-021-00614-6","volume":"16","author":"S Dagamajalu","year":"2022","unstructured":"Dagamajalu S, Rex DAB, Philem PD, Rainey JK, Keshava Prasad TS (2022a) A network map of apelin-mediated signaling. J Cell Commun Signal 16(1):137\u2013143","journal-title":"J Cell Commun Signal"},{"issue":"1","key":"672_CR13","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s12079-021-00640-4","volume":"16","author":"S Dagamajalu","year":"2022","unstructured":"Dagamajalu S, Rex DAB, Suchitha GP, Rai AB, Rainey JK, Prasad TSK (2022b) The network map of Elabela signaling pathway in physiological and pathological conditions. J Cell Commun Signal 16(1):145\u2013154","journal-title":"J Cell Commun Signal"},{"issue":"22","key":"672_CR14","doi-asserted-by":"publisher","first-page":"4424","DOI":"10.1091\/mbc.e10-12-0971","volume":"22","author":"I Diebold","year":"2011","unstructured":"Diebold I, Petry A, Burger M, Hess J, Gorlach A (2011) NOX4 mediates activation of FoxO3a and matrix metalloproteinase-2 expression by urotensin-II. Mol Biol Cell 22(22):4424\u20134434","journal-title":"Mol Biol Cell"},{"issue":"5","key":"672_CR15","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1160\/TH07-04-0294","volume":"98","author":"T Djordjevic","year":"2007","unstructured":"Djordjevic T, Gorlach A (2007) Urotensin-II in the lung: a matter for vascular remodelling and pulmonary hypertension? Thromb Haemost 98(5):952\u2013962","journal-title":"Thromb Haemost"},{"issue":"6","key":"672_CR16","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S1050-1738(00)00069-4","volume":"10","author":"SA Douglas","year":"2000","unstructured":"Douglas SA, Ohlstein EH (2000) Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease. Trends Cardiovasc Med 10(6):229\u2013237","journal-title":"Trends Cardiovasc Med"},{"issue":"2","key":"672_CR17","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.tips.2003.12.005","volume":"25","author":"SA Douglas","year":"2004","unstructured":"Douglas SA, Dhanak D, Johns DG (2004) From \u2018gills to pills\u2019: urotensin-II as a regulator of mammalian cardiorenal function. Trends Pharmacol Sci 25(2):76\u201385","journal-title":"Trends Pharmacol Sci"},{"issue":"2","key":"672_CR18","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2174\/1568009616666160621101248","volume":"17","author":"A Federico","year":"2017","unstructured":"Federico A, Zappavigna S, Dallio M, Misso G, Merlino F, Loguercio C, Novellino E, Grieco P, Caraglia M (2017) Urotensin-II receptor: a double identity receptor involved in vasoconstriction and in the development of digestive tract cancers and other tumors. Curr Cancer Drug Targets 17(2):109\u2013121","journal-title":"Curr Cancer Drug Targets"},{"issue":"4","key":"672_CR19","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1046\/j.1471-4159.2002.01196.x","volume":"83","author":"CM Filipeanu","year":"2002","unstructured":"Filipeanu CM, Brailoiu E, Le Dun S, Dun NJ (2002) Urotensin-II regulates intracellular calcium in dissociated rat spinal cord neurons. J Neurochem 83(4):879\u2013884","journal-title":"J Neurochem"},{"issue":"12","key":"672_CR20","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1111\/j.2042-7158.1988.tb06298.x","volume":"40","author":"A Gibson","year":"1988","unstructured":"Gibson A, Conyers S, Bern HA (1988) The influence of urotensin II on calcium flux in rat aorta. J Pharm Pharmacol 40(12):893\u2013895","journal-title":"J Pharm Pharmacol"},{"issue":"38","key":"672_CR21","doi-asserted-by":"publisher","first-page":"61152","DOI":"10.18632\/oncotarget.10748","volume":"7","author":"AA Goldberg","year":"2016","unstructured":"Goldberg AA, Joung KB, Mansuri A, Kang Y, Echavarria R, Nikolajev L, Sun Y, Yu JJ, Laporte SA, Schwertani A, Kristof AS (2016) Oncogenic effects of urotensin-II in cells lacking tuberous sclerosis complex-2. Oncotarget 7(38):61152\u201361165","journal-title":"Oncotarget"},{"issue":"7","key":"672_CR22","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1016\/j.peptides.2010.04.009","volume":"31","author":"D Gruson","year":"2010","unstructured":"Gruson D, Ginion A, Decroly N, Lause P, Vanoverschelde JL, Ketelslegers JM, Bertrand L, Thissen JP (2010) Urotensin II induction of adult cardiomyocytes hypertrophy involves the Akt\/GSK-3beta signaling pathway. Peptides 31(7):1326\u20131333","journal-title":"Peptides"},{"issue":"2","key":"672_CR23","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/sj.bjp.0705251","volume":"139","author":"CL Herold","year":"2003","unstructured":"Herold CL, Behm DJ, Buckley PT, Foley JJ, Wixted WE, Sarau HM, Douglas SA (2003) The neuromedin B receptor antagonist, BIM-23127, is a potent antagonist at human and rat urotensin-II receptors. Br J Pharmacol 139(2):203\u2013207","journal-title":"Br J Pharmacol"},{"issue":"4","key":"672_CR24","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1007\/s00210-004-0980-z","volume":"370","author":"DG Johns","year":"2004","unstructured":"Johns DG, Ao Z, Naselsky D, Herold CL, Maniscalco K, Sarov-Blat L, Steplewski K, Aiyar N, Douglas SA (2004) Urotensin-II-mediated cardiomyocyte hypertrophy: effect of receptor antagonism and role of inflammatory mediators. Naunyn Schmiedebergs Arch Pharmacol 370(4):238\u2013250","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"1","key":"672_CR25","doi-asserted-by":"publisher","first-page":"R3","DOI":"10.1186\/gb-2010-11-1-r3","volume":"11","author":"K Kandasamy","year":"2010","unstructured":"Kandasamy K, Mohan SS, Raju R, Keerthikumar S, Kumar GS, Venugopal AK, Telikicherla D, Navarro JD, Mathivanan S, Pecquet C, Gollapudi SK, Tattikota SG, Mohan S, Padhukasahasram H, Subbannayya Y, Goel R, Jacob HK, Zhong J, Sekhar R, Nanjappa V, Balakrishnan L, Subbaiah R, Ramachandra YL, Rahiman BA, Prasad TS, Lin JX, Houtman JC, Desiderio S, Renauld JC, Constantinescu SN, Ohara O, Hirano T, Kubo M, Singh S, Khatri P, Draghici S, Bader GD, Sander C, Leonard WJ, Pandey A (2010) NetPath: a public resource of curated signal transduction pathways. Genome Biol 11(1):R3","journal-title":"Genome Biol"},{"key":"672_CR26","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.ejphar.2017.03.056","volume":"803","author":"MY Kim","year":"2017","unstructured":"Kim MY, Ilyosbek S, Lee BH, Yi KY, Jung YS (2017a) A novel urotensin II receptor antagonist, KR-36676, prevents ABCA1 repression via ERK\/IL-1beta pathway. Eur J Pharmacol 803:174\u2013178","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"672_CR27","doi-asserted-by":"publisher","first-page":"308","DOI":"10.4062\/biomolther.2016.219","volume":"25","author":"TH Kim","year":"2017","unstructured":"Kim TH, Lee DG, Kim YA, Lee BH, Yi KY, Jung YS (2017b) A novel urotensin II receptor antagonist, KR-36996 inhibits smooth muscle proliferation through ERK\/ROS pathway. Biomol Ther (Seoul) 25(3):308\u2013314","journal-title":"Biomol Ther (Seoul)"},{"issue":"5","key":"672_CR28","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/S0272-6386(04)01130-8","volume":"44","author":"RG Langham","year":"2004","unstructured":"Langham RG, Kelly DJ, Gow RM, Zhang Y, Dowling JK, Thomson NM, Gilbert RE (2004) Increased expression of urotensin II and urotensin II receptor in human diabetic nephropathy. Am J Kidney Dis 44(5):826\u2013831","journal-title":"Am J Kidney Dis"},{"issue":"23","key":"672_CR29","doi-asserted-by":"publisher","first-page":"7432","DOI":"10.1021\/jm900683d","volume":"52","author":"EC Lawson","year":"2009","unstructured":"Lawson EC, Luci DK, Ghosh S, Kinney WA, Reynolds CH, Qi J, Smith CE, Wang Y, Minor LK, Haertlein BJ, Parry TJ, Damiano BP, Maryanoff BE (2009) Nonpeptide urotensin-II receptor antagonists: a new ligand class based on piperazino-phthalimide and piperazino-isoindolinone subunits. J Med Chem 52(23):7432\u20137445","journal-title":"J Med Chem"},{"issue":"4","key":"672_CR30","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.bbrc.2015.09.148","volume":"467","author":"W Li","year":"2015","unstructured":"Li W, Cai Z, Liu M, Zhao C, Li D, Lv C, Wang Y, Xu T (2015) Urotensin II contributes to collagen synthesis and up-regulates Egr-1 expression in cultured pulmonary arterial smooth muscle cells through the ERK1\/2 pathway. Biochem Biophys Res Commun 467(4):1076\u20131082","journal-title":"Biochem Biophys Res Commun"},{"issue":"25","key":"672_CR31","doi-asserted-by":"publisher","first-page":"5769","DOI":"10.3748\/wjg.v22.i25.5769","volume":"22","author":"YY Li","year":"2016","unstructured":"Li YY, Shi ZM, Yu XY, Feng P, Wang XJ (2016) Urotensin II-induced insulin resistance is mediated by NADPH oxidase-derived reactive oxygen species in HepG2 cells. World J Gastroenterol 22(25):5769\u20135779","journal-title":"World J Gastroenterol"},{"key":"672_CR32","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.peptides.2016.12.005","volume":"88","author":"YY Li","year":"2017","unstructured":"Li YY, Shi ZM, Yu XT, Feng P, Wang XJ (2017) The effects of urotensin II on migration and invasion are mediated by NADPH oxidase-derived reactive oxygen species through the c-Jun N-terminal kinase pathway in human hepatoma cells. Peptides 88:106\u2013114","journal-title":"Peptides"},{"issue":"6","key":"672_CR33","doi-asserted-by":"publisher","first-page":"e64895","DOI":"10.1371\/journal.pone.0064895","volume":"8","author":"DY Liang","year":"2014","unstructured":"Liang DY, Liu LM, Ye CG, Zhao L, Yu FP, Gao DY, Wang YY, Yang ZW, Wang YY (2014) Inhibition of UII\/UTR system relieves acute inflammation of liver through preventing activation of NF-kappaB pathway in ALF mice. PLoS ONE 8(6):e64895","journal-title":"PLoS ONE"},{"issue":"1","key":"672_CR34","doi-asserted-by":"publisher","first-page":"4214","DOI":"10.1038\/s41598-017-04086-w","volume":"7","author":"TL Liao","year":"2017","unstructured":"Liao TL, Chen YM, Hsieh CW, Chen HH, Lee HC, Hung WT, Tang KT, Chen DY (2017) Upregulation of circulating microRNA-134 in adult-onset Still\u2019s disease and its use as potential biomarker. Sci Rep 7(1):4214","journal-title":"Sci Rep"},{"issue":"6","key":"672_CR35","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1124\/mol.109.058297","volume":"76","author":"JC Liu","year":"2009","unstructured":"Liu JC, Chen CH, Chen JJ, Cheng TH (2009) Urotensin II induces rat cardiomyocyte hypertrophy via the transient oxidization of Src homology 2-containing tyrosine phosphatase and transactivation of epidermal growth factor receptor. Mol Pharmacol 76(6):1186\u20131195","journal-title":"Mol Pharmacol"},{"issue":"3","key":"672_CR36","doi-asserted-by":"publisher","first-page":"e0121383","DOI":"10.1371\/journal.pone.0121383","volume":"10","author":"LM Liu","year":"2015","unstructured":"Liu LM, Liang DY, Ye CG, Tu WJ, Zhu T (2015a) The UII\/UT system mediates upregulation of proinflammatory cytokines through p38 MAPK and NF-kappaB pathways in LPS-stimulated Kupffer cells. PLoS ONE 10(3):e0121383","journal-title":"PLoS ONE"},{"issue":"5","key":"672_CR37","doi-asserted-by":"publisher","first-page":"6626","DOI":"10.3892\/mmr.2015.4244","volume":"12","author":"W Liu","year":"2015","unstructured":"Liu W, Han Q, Liu Q, Liang G, Wang J, Liu C (2015b) An investigation into the expression and mechanism of action of urotensin II in chronic pressure-overloaded rat hearts. Mol Med Rep 12(5):6626\u20136634","journal-title":"Mol Med Rep"},{"issue":"31","key":"672_CR38","doi-asserted-by":"publisher","first-page":"49027","DOI":"10.18632\/oncotarget.10717","volume":"7","author":"LM Liu","year":"2016","unstructured":"Liu LM, Tu WJ, Zhu T, Wang XT, Tan ZL, Zhong H, Gao DY, Liang DY (2016) IRF3 is an important molecule in the UII\/UT system and mediates immune inflammatory injury in acute liver failure. Oncotarget 7(31):49027\u201349041","journal-title":"Oncotarget"},{"issue":"4","key":"672_CR39","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.5114\/aoms.2019.85197","volume":"15","author":"D Lu","year":"2019","unstructured":"Lu D, Peng F, Li J, Zhao J, Ye X, Li B, Ding W (2019) Urotensin II promotes secretion of LTB4 through 5-lipoxygenase via the UT-ROS-Akt pathway in RAW264.7 macrophages. Arch Med Sci 15(4):1065\u20131072","journal-title":"Arch Med Sci"},{"issue":"6","key":"672_CR40","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1023\/A:1009236126053","volume":"8","author":"OV Muravenko","year":"2000","unstructured":"Muravenko OV, Gizatullin RZ, Al-Amin AN, Protopopov AI, Kashuba VI, Zelenin AV, Zabarovsky ER (2000) Human ALY\/BEF gene Map position 17q25.3. Chromosome Res 8(6):562","journal-title":"Chromosome Res"},{"issue":"1","key":"672_CR41","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s10557-005-6899-x","volume":"19","author":"KL Ong","year":"2005","unstructured":"Ong KL, Lam KS, Cheung BM (2005) Urotensin II: its function in health and its role in disease. Cardiovasc Drugs Ther 19(1):65\u201375","journal-title":"Cardiovasc Drugs Ther"},{"issue":"4","key":"672_CR42","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1159\/000443445","volume":"41","author":"XX Pang","year":"2016","unstructured":"Pang XX, Bai Q, Wu F, Chen GJ, Zhang AH, Tang CS (2016) Urotensin II induces ER stress and EMT and increase extracellular matrix production in renal tubular epithelial cell in early diabetic mice. Kidney Blood Press Res 41(4):434\u2013449","journal-title":"Kidney Blood Press Res"},{"issue":"1\u20132","key":"672_CR43","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s11010-016-2814-y","volume":"422","author":"CH Park","year":"2016","unstructured":"Park CH, Lee JH, Lee MY, Lee JH, Lee BH, Oh KS (2016) A novel role of G protein-coupled receptor kinase 5 in urotensin II-stimulated cellular hypertrophy in H9c2UT cells. Mol Cell Biochem 422(1\u20132):151\u2013160","journal-title":"Mol Cell Biochem"},{"issue":"7","key":"672_CR44","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1038\/sj.bjp.0705555","volume":"140","author":"R Patacchini","year":"2003","unstructured":"Patacchini R, Santicioli P, Giuliani S, Grieco P, Novellino E, Rovero P, Maggi CA (2003) Urantide: an ultrapotent urotensin II antagonist peptide in the rat aorta. Br J Pharmacol 140(7):1155\u20131158","journal-title":"Br J Pharmacol"},{"issue":"8","key":"672_CR45","doi-asserted-by":"publisher","first-page":"5021","DOI":"10.1073\/pnas.77.8.5021","volume":"77","author":"D Pearson","year":"1980","unstructured":"Pearson D, Shively JE, Clark BR, Geschwind II, Barkley M, Nishioka RS, Bern HA (1980) Urotensin II: a somatostatin-like peptide in the caudal neurosecretory system of fishes. Proc Natl Acad Sci USA 77(8):5021\u20135024","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"672_CR46","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S0014-2999(00)00672-5","volume":"406","author":"O Saetrum Opgaard","year":"2000","unstructured":"Saetrum Opgaard O, Nothacker H, Ehlert FJ, Krause DN (2000) Human urotensin II mediates vasoconstriction via an increase in inositol phosphates. Eur J Pharmacol 406(2):265\u2013271","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"672_CR47","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.gene.2016.02.039","volume":"583","author":"H Shi","year":"2016","unstructured":"Shi H, Han Q, Xu J, Liu W, Chu T, Zhao L (2016) Urotensin II induction of neonatal cardiomyocyte hypertrophy involves the CaMKII\/PLN\/SERCA 2a signaling pathway. Gene 583(1):8\u201314","journal-title":"Gene"},{"issue":"2","key":"672_CR48","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/s00210-006-0057-2","volume":"373","author":"W Song","year":"2006","unstructured":"Song W, McDonald J, Camarda V, Calo G, Guerrini R, Marzola E, Thompson JP, Rowbotham DJ, Lambert DG (2006) Cell and tissue responses of a range of urotensin II analogs at cloned and native urotensin II receptors. Evidence for coupling promiscuity. Naunyn Schmiedebergs Arch Pharmacol 373(2):148\u2013157","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"1","key":"672_CR49","doi-asserted-by":"publisher","first-page":"18049","DOI":"10.1038\/s41598-017-18143-x","volume":"7","author":"H Soni","year":"2017","unstructured":"Soni H, Adebiyi A (2017) Urotensin II-induced store-operated Ca(2+) entry contributes to glomerular mesangial cell proliferation and extracellular matrix protein production under high glucose conditions. Sci Rep 7(1):18049","journal-title":"Sci Rep"},{"issue":"3","key":"672_CR50","doi-asserted-by":"publisher","first-page":"e0118879","DOI":"10.1371\/journal.pone.0118879","volume":"10","author":"PO Staff","year":"2015","unstructured":"Staff PO (2015) Correction: urotensin II inhibits doxorubicin-induced human umbilical vein endothelial cell death by modulating ATF expression and via the ERK and Akt pathway. PLoS ONE 10(3):e0118879","journal-title":"PLoS ONE"},{"key":"672_CR51","doi-asserted-by":"publisher","DOI":"10.1530\/JOE-18-0505","author":"SL Sun","year":"2019","unstructured":"Sun SL, Liu LM (2019) Urotensin II: an inflammatory cytokine. J Endocrinol. https:\/\/doi.org\/10.1530\/JOE-18-0505","journal-title":"J Endocrinol"},{"issue":"6","key":"672_CR52","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.3892\/ijmm.2016.2789","volume":"38","author":"L Tian","year":"2016","unstructured":"Tian L, Fu P, Zhou M, Gu Y, Li Y, Qi J (2016) Role of urotensin II in advanced glycation end product-induced extracellular matrix synthesis in rat proximal tubular epithelial cells. Int J Mol Med 38(6):1831\u20131838","journal-title":"Int J Mol Med"},{"issue":"7","key":"672_CR53","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1073\/pnas.0510700103","volume":"103","author":"H Tostivint","year":"2006","unstructured":"Tostivint H, Joly L, Lihrmann I, Parmentier C, Lebon A, Morisson M, Calas A, Ekker M, Vaudry H (2006) Comparative genomics provides evidence for close evolutionary relationships between the urotensin II and somatostatin gene families. Proc Natl Acad Sci USA 103(7):2237\u20132242","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"672_CR54","doi-asserted-by":"publisher","first-page":"H608","DOI":"10.1152\/ajpheart.00942.2009","volume":"298","author":"L Tran","year":"2010","unstructured":"Tran L, Kompa AR, Kemp W, Phrommintikul A, Wang BH, Krum H (2010) Chronic urotensin-II infusion induces diastolic dysfunction and enhances collagen production in rats. Am J Physiol Heart Circ Physiol 298(2):H608\u2013H613","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"672_CR55","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3389\/fphar.2011.00038","volume":"2","author":"P Tsoukas","year":"2011","unstructured":"Tsoukas P, Kane E, Giaid A (2011) Potential clinical implications of the urotensin II receptor antagonists. Front Pharmacol 2:38","journal-title":"Front Pharmacol"},{"issue":"3","key":"672_CR56","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1161\/01.RES.0000084382.64418.BC","volume":"93","author":"A Tzanidis","year":"2003","unstructured":"Tzanidis A, Hannan RD, Thomas WG, Onan D, Autelitano DJ, See F, Kelly DJ, Gilbert RE, Krum H (2003) Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy. Circ Res 93(3):246\u2013253","journal-title":"Circ Res"},{"key":"672_CR57","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1186\/1471-2105-9-399","volume":"9","author":"MP van Iersel","year":"2008","unstructured":"van Iersel MP, Kelder T, Pico AR, Hanspers K, Coort S, Conklin BR, Evelo C (2008) Presenting and exploring biological pathways with PathVisio. BMC Bioinformatics 9:399","journal-title":"BMC Bioinformatics"},{"key":"672_CR58","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/j.1749-6632.2010.05514.x","volume":"1200","author":"H Vaudry","year":"2010","unstructured":"Vaudry H, Do Rego JC, Le Mevel JC, Chatenet D, Tostivint H, Fournier A, Tonon MC, Pelletier G, Conlon JM, Leprince J (2010) Urotensin II, from fish to human. Ann N Y Acad Sci 1200:53\u201366","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"672_CR59","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1124\/pr.114.009480","volume":"67","author":"H Vaudry","year":"2015","unstructured":"Vaudry H, Leprince J, Chatenet D, Fournier A, Lambert DG, Le Mevel JC, Ohlstein EH, Schwertani A, Tostivint H, Vaudry D (2015) International union of basic and clinical pharmacology. XCII. Urotensin II, urotensin II-related peptide, and their receptor: from structure to function. Pharmacol Rev 67(1):214\u2013258","journal-title":"Pharmacol Rev"},{"issue":"4","key":"672_CR60","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.bbrc.2014.09.030","volume":"452","author":"Y Wang","year":"2014","unstructured":"Wang Y, Wu JF, Tang YY, Zhang M, Li Y, Chen K, Zeng MY, Yao F, Xie W, Zheng XL, Zeng GF, Tang CK (2014) Urotensin II increases foam cell formation by repressing ABCA1 expression through the ERK\/NF-kappaB pathway in THP-1 macrophages. Biochem Biophys Res Commun 452(4):998\u20131003","journal-title":"Biochem Biophys Res Commun"},{"key":"672_CR61","doi-asserted-by":"publisher","first-page":"117421","DOI":"10.1016\/j.lfs.2020.117421","volume":"247","author":"T Wang","year":"2020","unstructured":"Wang T, Xie YQ, Miao GX, Cui HP, Liu K, Li Y, Li Y, Zhao J (2020) Urotensin receptor antagonist urantide improves atherosclerosis-related kidney injury by inhibiting JAK2\/STAT3 signaling pathway in rats. Life Sci 247:117421","journal-title":"Life Sci"},{"issue":"4","key":"672_CR62","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1161\/01.HYP.0000184226.99196.b5","volume":"46","author":"T Watanabe","year":"2005","unstructured":"Watanabe T, Suguro T, Kanome T, Sakamoto Y, Kodate S, Hagiwara T, Hongo S, Hirano T, Adachi M, Miyazaki A (2005) Human urotensin II accelerates foam cell formation in human monocyte-derived macrophages. Hypertension 46(4):738\u2013744","journal-title":"Hypertension"},{"issue":"12","key":"672_CR70","doi-asserted-by":"publisher","first-page":"20768","DOI":"10.3390\/molecules191220768","volume":"19","author":"Xiao-Tong Yu","year":"2014","unstructured":"Yu XT, Wang PY, Shi ZM, Dong K, Feng P, Wang HX, Wang XJ (2014) Up-regulation of urotensin ii and its receptor contributes to human hepatocellular carcinoma growth via activation of the PKC ERK1\/2 and p38 MAPK signaling pathways. Molecules 19(12):20768\u201320779. https:\/\/doi.org\/10.3390\/molecules191220768","journal-title":"Molecules"},{"issue":"12","key":"672_CR63","doi-asserted-by":"publisher","first-page":"e0144433","DOI":"10.1371\/journal.pone.0144433","volume":"10","author":"X Yu","year":"2015","unstructured":"Yu X, Wang P, Shi Z, Dong K, Feng P, Wang H, Wang X (2015) Urotensin-II-mediated reactive oxygen species generation via NADPH oxidase pathway contributes to hepatic oval cell proliferation. PLoS ONE 10(12):e0144433","journal-title":"PLoS ONE"},{"issue":"13","key":"672_CR64","doi-asserted-by":"publisher","first-page":"8644","DOI":"10.1074\/jbc.M114.615021","volume":"290","author":"Y Zhang","year":"2015","unstructured":"Zhang Y, Ying J, Jiang D, Chang Z, Li H, Zhang G, Gong S, Jiang X, Tao J (2015) Urotensin-II receptor stimulation of cardiac L-type Ca2+ channels requires the betagamma subunits of Gi\/o-protein and phosphatidylinositol 3-kinase-dependent protein kinase C beta1 isoform. J Biol Chem 290(13):8644\u20138655","journal-title":"J Biol Chem"},{"key":"672_CR65","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.regpep.2012.12.006","volume":"182","author":"J Zhao","year":"2013","unstructured":"Zhao J, Ding W, Song N, Dong X, Di B, Peng F, Tang C (2013) Urotensin II-induced collagen synthesis in cultured smooth muscle cells from rat aortic media and a possible involvement of transforming growth factor-beta1\/Smad2\/3 signaling pathway. Regul Pept 182:53\u201358","journal-title":"Regul Pept"},{"key":"672_CR66","doi-asserted-by":"publisher","first-page":"118551","DOI":"10.1016\/j.lfs.2020.118551","volume":"262","author":"J Zhao","year":"2020","unstructured":"Zhao J, Miao G, Wang T, Li J, Xie L (2020) Urantide attenuates myocardial damage in atherosclerotic rats by regulating the MAPK signalling pathway. Life Sci 262:118551","journal-title":"Life Sci"},{"issue":"6","key":"672_CR67","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.3892\/ol.2012.932","volume":"4","author":"CH Zhou","year":"2012","unstructured":"Zhou CH, Wan YY, Chu XH, Song Z, Xing SH, Wu YQ, Yin XX (2012) Urotensin II contributes to the formation of lung adenocarcinoma inflammatory microenvironment through the NF-kappaB pathway in tumor-bearing nude mice. Oncol Lett 4(6):1259\u20131263","journal-title":"Oncol Lett"},{"issue":"7","key":"672_CR68","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1038\/sj.bjp.0706800","volume":"148","author":"YC Zhu","year":"2006","unstructured":"Zhu YC, Zhu YZ, Moore PK (2006) The role of urotensin II in cardiovascular and renal physiology and diseases. Br J Pharmacol 148(7):884\u2013901","journal-title":"Br J Pharmacol"},{"issue":"1","key":"672_CR69","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0014-5793(01)03015-0","volume":"508","author":"Y Zou","year":"2001","unstructured":"Zou Y, Nagai R, Yamazaki T (2001) Urotensin II induces hypertrophic responses in cultured cardiomyocytes from neonatal rats. FEBS Lett 508(1):57\u201360","journal-title":"FEBS Lett"}],"container-title":["Journal of Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12079-022-00672-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12079-022-00672-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12079-022-00672-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T19:07:03Z","timestamp":1702667223000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12079-022-00672-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,16]]},"references-count":70,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["672"],"URL":"https:\/\/doi.org\/10.1007\/s12079-022-00672-4","relation":{},"ISSN":["1873-9601","1873-961X"],"issn-type":[{"value":"1873-9601","type":"print"},{"value":"1873-961X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,16]]},"assertion":[{"value":"29 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors report no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}